Özlem Nuray Sever

427 total citations
38 papers, 278 citations indexed

About

Özlem Nuray Sever is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Özlem Nuray Sever has authored 38 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Özlem Nuray Sever's work include Cancer Immunotherapy and Biomarkers (9 papers), Renal cell carcinoma treatment (8 papers) and Inflammatory Biomarkers in Disease Prognosis (6 papers). Özlem Nuray Sever is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Renal cell carcinoma treatment (8 papers) and Inflammatory Biomarkers in Disease Prognosis (6 papers). Özlem Nuray Sever collaborates with scholars based in Türkiye, India and Antigua and Barbuda. Özlem Nuray Sever's co-authors include Ertan Şahin, Umut Elboğa, Y. Zeki Çelen, Osman Demir, Fatih Teker, Havva Yeşil Çınkır, Benan Kılbaş, Aydın Aytekin, Gökmen Aktaş and Tülay Kuş and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Özlem Nuray Sever

32 papers receiving 276 citations

Peers

Özlem Nuray Sever
Aydın Aytekin Türkiye
Emine Göknur Işık Türkiye
Dominik Leitz Germany
Wichit Arpornwirat Thailand
Yaqing Dai China
Yiwei Tong China
Weiqing Han China
Lyudmila Zhukova Russia
Kojiro Tashiro Japan
Diego Márquez-Medina Spain
Aydın Aytekin Türkiye
Özlem Nuray Sever
Citations per year, relative to Özlem Nuray Sever Özlem Nuray Sever (= 1×) peers Aydın Aytekin

Countries citing papers authored by Özlem Nuray Sever

Since Specialization
Citations

This map shows the geographic impact of Özlem Nuray Sever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Özlem Nuray Sever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Özlem Nuray Sever more than expected).

Fields of papers citing papers by Özlem Nuray Sever

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Özlem Nuray Sever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Özlem Nuray Sever. The network helps show where Özlem Nuray Sever may publish in the future.

Co-authorship network of co-authors of Özlem Nuray Sever

This figure shows the co-authorship network connecting the top 25 collaborators of Özlem Nuray Sever. A scholar is included among the top collaborators of Özlem Nuray Sever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Özlem Nuray Sever. Özlem Nuray Sever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kuzu, Omer F., Sung Hoon Sim, Deniz Tural, et al.. (2025). Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma. BMC Cancer. 25(1). 1220–1220.
3.
Sever, Özlem Nuray, et al.. (2025). Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer. Journal of Clinical Medicine. 14(4). 1302–1302. 1 indexed citations
4.
Alan, Özkan, et al.. (2024). Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis. Medicina. 60(8). 1374–1374. 4 indexed citations
5.
6.
Alan, Özkan, et al.. (2024). Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older. Journal of Clinical Medicine. 13(20). 6263–6263. 1 indexed citations
7.
Alan, Özkan, et al.. (2024). The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy. Scientific Reports. 14(1). 12123–12123. 6 indexed citations
8.
Sever, Özlem Nuray, et al.. (2024). Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?. Medicina. 60(8). 1372–1372. 2 indexed citations
9.
Kuzu, Omer F., Deniz Tural, Sung Hoon Sim, et al.. (2024). Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Clinical Genitourinary Cancer. 23(1). 102282–102282. 1 indexed citations
10.
11.
12.
Yekedüz, Emre, Deniz Tural, Özlem Erçelep, et al.. (2022). The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. Scientific Reports. 12(1). 16559–16559. 10 indexed citations
13.
Elboğa, Umut, Ertan Şahin, Tülay Kuş, et al.. (2022). Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement. Molecular Imaging and Biology. 24(5). 789–797. 30 indexed citations
14.
Sever, Özlem Nuray, et al.. (2022). 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 42(2). 71–76. 3 indexed citations
15.
Şahin, Ertan, et al.. (2021). Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. European Journal of Radiology. 142. 109867–109867. 51 indexed citations
16.
Elboğa, Umut, Ertan Şahin, Tülay Kuş, et al.. (2021). Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Annals of Nuclear Medicine. 35(12). 1321–1331. 72 indexed citations
17.
Yekedüz, Emre, Deniz Tural, Nuri Karadurmuş, et al.. (2021). Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. Journal of Clinical Oncology. 39(6_suppl). 321–321. 1 indexed citations
18.
19.
Bozcuk, Hakan, et al.. (2020). Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis. Journal of Cancer Research and Therapeutics. 16(4). 828–828. 6 indexed citations
20.
Camcı, Celalettin, Alper Sevinç, Mehmet Kalender, et al.. (2011). Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients. Tumor Biology. 32(6). 1265–1270. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aydın Aytekin Breakdown of academic impact, for papers by Emine Göknur Işık Breakdown of academic impact, for papers by Dominik Leitz Breakdown of academic impact, for papers by Wichit Arpornwirat Breakdown of academic impact, for papers by Yaqing Dai Breakdown of academic impact, for papers by Yiwei Tong Breakdown of academic impact, for papers by Weiqing Han Breakdown of academic impact, for papers by Lyudmila Zhukova Breakdown of academic impact, for papers by Kojiro Tashiro Breakdown of academic impact, for papers by Diego Márquez-Medina
Rankless by CCL
2026